Toward Precision Radiotherapy for Use with Immune Checkpoint Blockers

Area of Science:

• Immunology
• Radiation Oncology
• Cancer Therapy

Background:

• Evidence suggests radiotherapy enhances immune checkpoint blocker (ICB) efficacy, initially observed in mouse models and later confirmed in clinical settings.
• The pro-immunogenic effects of radiation have been clinically validated, with some patients responding systemically to ICB therapy after localized radiation.
• While synergy between radiotherapy and immunomodulators is known, the impact of radiation dose and fractionation on immunostimulatory potential requires thorough investigation.

Purpose of the Study:

• To investigate the impact of radiotherapy dose and fractionation on its immunostimulatory potential.
• To explore the underlying mechanisms by which radiotherapy enhances anti-tumor immunity in conjunction with ICBs.
• To discuss strategies for optimizing radiotherapy use and identify potential biomarkers for predicting response to combined therapies.

Main Methods:

• Review of preclinical data demonstrating synergy between radiotherapy and immunomodulators.
• Analysis of recent findings on radiotherapy-induced recruitment of dendritic cells and priming of CD8+ T cells.
• Discussion of molecular mechanisms involving cytoplasmic double-stranded DNA and type I Interferon (IFN) release.

Main Results:

• Radiotherapy dose and fractionation significantly influence the recruitment of dendritic cells to tumors, impacting the priming of tumor-specific CD8+ T cells.
• A mechanism involving cytoplasmic double-stranded DNA accumulation in cancer cells and subsequent type I IFN release is implicated in radiotherapy's immunostimulatory effects.
• The molecular links between cellular responses to radiotherapy and type I IFN secretion are actively being uncovered.

Conclusions:

• Optimizing radiotherapy dose and fractionation is essential for maximizing its synergistic effects with ICBs.
• Understanding the molecular mechanisms underlying radiotherapy's immunomodulatory effects can guide the development of more effective combination therapies.
• Identification of predictive biomarkers is crucial for selecting patients who will benefit from combined radiotherapy and ICB treatment.